News
Esketamine Monotherapy Safe, Effective for TRD: Phase 4 Data Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results